Cargando…

SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021

To compare SARS-CoV-2 antibody seroprevalence among children with seropositive confirmed COVID-19 case counts (case ascertainment by molecular amplification) in Colorado, USA, we conducted a cross-sectional serosurvey during May–July 2021. For a convenience sample of 829 Colorado children, SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Shannon C., Cole, Lyndsey D., Albanese, Bernadette A., Mahon, Allison, Knight, Vijaya, Williams, Nathan, Severson, Rachel, Burakoff, Alexis, Alden, Nisha B., Dominguez, Samuel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124638/
https://www.ncbi.nlm.nih.gov/pubmed/36972709
http://dx.doi.org/10.3201/eid2905.221541
_version_ 1785029878465167360
author O’Brien, Shannon C.
Cole, Lyndsey D.
Albanese, Bernadette A.
Mahon, Allison
Knight, Vijaya
Williams, Nathan
Severson, Rachel
Burakoff, Alexis
Alden, Nisha B.
Dominguez, Samuel R.
author_facet O’Brien, Shannon C.
Cole, Lyndsey D.
Albanese, Bernadette A.
Mahon, Allison
Knight, Vijaya
Williams, Nathan
Severson, Rachel
Burakoff, Alexis
Alden, Nisha B.
Dominguez, Samuel R.
author_sort O’Brien, Shannon C.
collection PubMed
description To compare SARS-CoV-2 antibody seroprevalence among children with seropositive confirmed COVID-19 case counts (case ascertainment by molecular amplification) in Colorado, USA, we conducted a cross-sectional serosurvey during May–July 2021. For a convenience sample of 829 Colorado children, SARS-CoV-2 seroprevalence was 36.7%, compared with prevalence of 6.5% according to individually matched COVID-19 test results reported to public health. Compared with non-Hispanic White children, seroprevalence was higher among Hispanic, non-Hispanic Black, and non-Hispanic other race children, and case ascertainment was significantly lower among Hispanic and non-Hispanic Black children. This serosurvey accurately estimated SARS-CoV-2 prevalence among children compared with confirmed COVID-19 case counts and revealed substantial racial/ethnic disparities in infections and case ascertainment. Continued efforts to address racial and ethnic differences in disease burden and to overcome potential barriers to case ascertainment, including access to testing, may help mitigate these ongoing disparities.
format Online
Article
Text
id pubmed-10124638
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-101246382023-05-01 SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021 O’Brien, Shannon C. Cole, Lyndsey D. Albanese, Bernadette A. Mahon, Allison Knight, Vijaya Williams, Nathan Severson, Rachel Burakoff, Alexis Alden, Nisha B. Dominguez, Samuel R. Emerg Infect Dis Research To compare SARS-CoV-2 antibody seroprevalence among children with seropositive confirmed COVID-19 case counts (case ascertainment by molecular amplification) in Colorado, USA, we conducted a cross-sectional serosurvey during May–July 2021. For a convenience sample of 829 Colorado children, SARS-CoV-2 seroprevalence was 36.7%, compared with prevalence of 6.5% according to individually matched COVID-19 test results reported to public health. Compared with non-Hispanic White children, seroprevalence was higher among Hispanic, non-Hispanic Black, and non-Hispanic other race children, and case ascertainment was significantly lower among Hispanic and non-Hispanic Black children. This serosurvey accurately estimated SARS-CoV-2 prevalence among children compared with confirmed COVID-19 case counts and revealed substantial racial/ethnic disparities in infections and case ascertainment. Continued efforts to address racial and ethnic differences in disease burden and to overcome potential barriers to case ascertainment, including access to testing, may help mitigate these ongoing disparities. Centers for Disease Control and Prevention 2023-05 /pmc/articles/PMC10124638/ /pubmed/36972709 http://dx.doi.org/10.3201/eid2905.221541 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
O’Brien, Shannon C.
Cole, Lyndsey D.
Albanese, Bernadette A.
Mahon, Allison
Knight, Vijaya
Williams, Nathan
Severson, Rachel
Burakoff, Alexis
Alden, Nisha B.
Dominguez, Samuel R.
SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021
title SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021
title_full SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021
title_fullStr SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021
title_full_unstemmed SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021
title_short SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021
title_sort sars-cov-2 seroprevalence compared with confirmed covid-19 cases among children, colorado, usa, may–july 2021
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124638/
https://www.ncbi.nlm.nih.gov/pubmed/36972709
http://dx.doi.org/10.3201/eid2905.221541
work_keys_str_mv AT obrienshannonc sarscov2seroprevalencecomparedwithconfirmedcovid19casesamongchildrencoloradousamayjuly2021
AT colelyndseyd sarscov2seroprevalencecomparedwithconfirmedcovid19casesamongchildrencoloradousamayjuly2021
AT albanesebernadettea sarscov2seroprevalencecomparedwithconfirmedcovid19casesamongchildrencoloradousamayjuly2021
AT mahonallison sarscov2seroprevalencecomparedwithconfirmedcovid19casesamongchildrencoloradousamayjuly2021
AT knightvijaya sarscov2seroprevalencecomparedwithconfirmedcovid19casesamongchildrencoloradousamayjuly2021
AT williamsnathan sarscov2seroprevalencecomparedwithconfirmedcovid19casesamongchildrencoloradousamayjuly2021
AT seversonrachel sarscov2seroprevalencecomparedwithconfirmedcovid19casesamongchildrencoloradousamayjuly2021
AT burakoffalexis sarscov2seroprevalencecomparedwithconfirmedcovid19casesamongchildrencoloradousamayjuly2021
AT aldennishab sarscov2seroprevalencecomparedwithconfirmedcovid19casesamongchildrencoloradousamayjuly2021
AT dominguezsamuelr sarscov2seroprevalencecomparedwithconfirmedcovid19casesamongchildrencoloradousamayjuly2021